Early stent procedure versus medicine alone for risky plaque in heart arteries
Compares early stenting plus medicine with medicine alone in coronary artery disease.
Key facts
- Who runs it
- Duk-Woo Park, MD
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography-2
- Status
- Not yet recruiting
- People taking part
- 2,500 people, planned
- Starts
- 30 Dec 2026
- Expected to end
- 31 Dec 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Initial Invasive Strategy
- Initial Conservative Strategy
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected coronary artery disease whose heart CT scan shows narrowed arteries with high-risk plaque features.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- At least moderate narrowing in one or more major heart arteries, with at least two high-risk plaque features on coronary CT angiography (low-attenuation plaque, positive remodeling, napkin-ring sign, or spotty calcification).
- Earlier treatment
- People who had a coronary artery bypass operation (CABG) before cannot join.
Main reasons for not taking part
- Acute coronary syndrome needing urgent invasive checks
- Significant left main coronary artery disease (50% narrowing or more)
- Heart pumping function (LVEF) below 35%, or heart failure class III or IV
- Severe kidney problems (eGFR below 30) or kidney failure on dialysis
- Pregnant, breastfeeding, or planning pregnancy during the study
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patients aged ≥18 years
- Patients with suspected coronary artery disease (CAD) (e.g., chest pain syndrome or equivalent symptoms) who are evaluated with coronary computed tomography angiography (CCTA)
- Coronary computed tomography angiography (CCTA) showing:; Plaque with at least moderate stenosis in one or more major epicardial coronary arteries; and; At least two high-risk plaque (HRP) feature at the site of stenotic lesions, defined as any of the following:; Low-attenuation plaque (LAP) (<70 Hounsfield units); Positive remodeling (PR) (remodeling index >1.2); Napkin-ring sign (NRS); Spotty calcification (SC) (<3 mm in length)
- Willing and able to provide written informed consent
Who cannot take part
- New York Heart Association (NYHA) class III or IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months
- Prior coronary artery bypass grafting (CABG)
- Contraindication to undergoing coronary computed tomography angiography (CTA) (e.g., allergy to radiographic contrast that cannot be adequately premedicated, any prior anaphylaxis to radiographic contrast, or inability to cooperate with scan acquisition)
- Contraindications to or planned discontinuation of dual antiplatelet therapy within 1 year
- Active participation in another interventional clinical trial involving an unapproved investigational drug or device
- Acute coronary syndrome (ACS) requiring urgent or emergent invasive evaluation
- Hemodynamically unstable conditions
- Significant left main coronary artery disease (≥50% diameter stenosis)
- Severe renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m²) or end-stage renal disease on dialysis
- Planned cardiac or major noncardiac surgery within the study period
- Left ventricular ejection fraction (LVEF) <35%; → Left ventricular ejection fraction <35%
- Coronary anatomy unsuitable for either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
- Life expectancy less than the duration of the trial due to non-cardiovascular comorbidity
- Women who are breastfeeding, pregnant, or planning to become pregnant during the course of the study
- Inability to comply with the study protocol
Where in South Korea
- Asan Medical CenterSeoul, South KoreaContact: Duk-woo Park Professor in Department of Cardiology, Asan Medical Center, MD, PhDNot yet recruiting
About the trial
What the trial wants to find out
The PREVENT-2 trial is to determine whether an initial invasive strategy-consisting of early coronary angiography (CAG) with intent for preventive percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT)-reduces the incidence of the primary composite outcome of cardiac death, target-vessel myocardial infarction (MI), unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years, compared with an initial conservative strategy of optimal medical therapy (OMT) alone, in patients with high-risk vulnerable plaque identified by coronary computed tomography angiography (CCTA).
The 2 groups in the trial
- Initial Invasive StrategyTreatment being tested
- Initial Conservative StrategyExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Comparison of Initial Invasive Strategy and Initial Conservative Strategy for the Treatment of Vulnerable Atherosclerotic Coronary Plaques Identified by Coronary CT Angiography
- Plain-language title
- Early stent procedure versus medicine alone for risky plaque in heart arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 October 2026